Taiwan Liposome Company (TLC)
2F, 3 Yuanqu Street
Nankang
Taipei
115
Tel: 886-2-2655-7377
Fax: 886-2-2655-7366
Website: http://www.tlcbio.com/
Email: info@tlcbio.com
About Taiwan Liposome Company (TLC)
Taiwan Liposome Company (TLC) is a biopharmaceutical company focused on the research, development and commercialization of innovative pharmaceutical products based on its proprietary drug delivery technologies. Our strengths lie in lipid-based formulation and scale-up for parenteral drugs using micelles and nanoparticles to optimize the pharmacokinetics of drugs for better efficacy and lower toxicity, and thus prolong the product lifecycle of branded drugs.YEAR FOUNDED:
1997
LEADERSHIP:
Founder and CEO: Keelung Hong
CFO: Nicole Lin
JOBS:
Please click here for TLC job opportunities.
CLINICAL TRIAL:
Please click here for clinical trial information.
FOLLOW TLC:
Tweets by TLC
69 articles about Taiwan Liposome Company (TLC)
-
TLC to Present Potential Cartilage-Protecting Effects of TLC599 on the Knee at 2019 ACR Annual Meeting
10/7/2019
MRI evaluation suggests slowing of cartilage damage and potential chondroprotection in osteoarthritis of the knee
-
TLC Announces Initiation of Phase III Pivotal Clinical Trial of TLC599 for the Treatment of Osteoarthritis Knee Pain
10/1/2019
TLC announced the initiation of a Phase III clinical trial (“EXCELLENCE”) to evaluate the efficacy and safety of single as well as repeated doses of TLC599 in patients with osteoarthritis (OA) of the knee.
-
TLC to Present Preclinical Data on TLC178 at ESMO 2019
9/23/2019
TLC178 shows potential as a treatment for sarcomas, with enhanced efficacy, reduced toxicity and decreased dosing frequency
-
TLC to Present as Panelist among Key Opinion Leaders at the BTIG Pain Management Forum
9/3/2019
TLC announced that the Company’s management team has been invited to participate in the BTIG Pain Management Forum on September 11, 2019, where TLC will present data on TLC599 and TLC590.
-
TLC to Present at Upcoming Investor Conferences in September 2019
8/28/2019
TLC announced that the management team is scheduled to present at the two upcoming investor conferences
-
TLC Reports Second Quarter 2019 Financial Results and Provides Business Update
7/30/2019
TLC announced financial results for the second quarter ended June 30, 2019, and provided a business update.
-
TLC Announces Development and License Agreement with Birdie Biopharmaceuticals for NanoX™ Immunotherapy Product
6/25/2019
Taiwan Liposome Company, Ltd. announced the signing of a development and license agreement with Birdie Biopharmaceuticals Inc., a wholly owned subsidiary of Seven and Eight Biopharmaceuticals Corp.
-
TLC Announces Part 1 Analysis of TLC590 Phase II Clinical Trial for Postsurgical Pain Management following Bunionectomy
6/14/2019
TLC, announced results from the pre-planned analysis of Part 1 of TLC590’s Phase II clinical trial in patients following bunionectomy.
-
TLC Presents New Pharmacokinetic and Toxicokinetic Data on TLC599 Following Intra-articular Injection in Dogs at EULAR 2019
6/12/2019
TLC599 showed locally sustained release profile up to 120 days, dose proportionality, minimal systemic exposure and potential for repeat dosing
-
TLC Reports First Quarter of 2019 Financial Results and Provides Business Update
5/8/2019
TLC announced financial results for the first quarter ended March 31, 2019, and provided a business update.
-
TLC Reports Positive Top-Line Results from Phase I/II Clinical Trial of TLC590 for Postsurgical Pain
3/11/2019
TLC590 demonstrated durable, statistically significant and clinically meaningful improvement over the standard of care through 96 hours
-
3SBio and TLC Form Exclusive Partnership to Commercialize Two NanoX™ Products in Mainland China
3/3/2019
3SBio Inc. and Taiwan Liposome Company, Ltd. announced an exclusive partnership to commercialize in mainland China two liposomal products utilizing TLC's proprietary NanoX™ technology platform in the therapeutic areas of oncology and severe infectious diseases.
-
TLC Appoints George Spencer-Green, MD, MS, as Chief Medical Officer
1/25/2019
Taiwan Liposome Company, Ltd. announced the appointment of George Spencer-Green, MD, MS, as TLC’s new Chief Medical Officer.
-
EMA Grants Orphan Drug Designation to TLC178 for the Treatment of Soft Tissue Sarcoma
1/22/2019
Taiwan Liposome Company, Ltd. today announced that the European Medicines Agency (EMA) has granted orphan drug designation for TLC178 for the treatment of soft tissue sarcoma.
-
The Nasdaq indicated that there was a record amount of biotech initial public offerings this year, including some individual record-breakers—Moderna, Allogene Therapeutics and Rubius Therapeutics. The total for the year is around $8.2 billion raised, breaking 2014’s record of $6.5 billion.
-
A summary of IPOs from companies in the biotech and pharma world since November 1, 2018.
-
TLC to Attend Goldman Sachs Asia Pacific Healthcare Forum 2018
11/25/2018
Taiwan Liposome Company, Ltd. today announced that it will be attending Goldman Sachs’ Asia Pacific Healthcare Forum in Hong Kong, at the JW Marriott Hotel on November 27-28, 2018.
-
TLC to Present Full Data from TLC599 Phase I/II Study in Knee Osteoarthritis at 20th Asia Pacific League of Associations for Rheumatology Congress
9/7/2018
Taiwan Liposome Company, Ltd. today announced that it will feature a poster presentation covering the complete dataset from its Phase I/II study of the company’s lead product candidate, TLC599, in patients with knee osteoarthritis at the 20th Asia Pacific League of Associations for Rheumatology Congress (APLAR),
-
First Patients in Phase I/II Trial of TLC590 for Postsurgical Pain Management
8/14/2018
Taiwan Liposome Company, Ltd. (4152.TWO; “TLC”), a clinical-stage specialty pharmaceutical company dedicated to the development and commercialization of novel nanomedicines designed to target areas of medical needs in pain management, ophthalmology, and oncology, today announced the dosing of the first patients in a Phase I/II trial for TLC590.
-
TLC Reports Last Patient Last Visit (LPLV) in TLC599 Phase II Trial and FDA Clearance to Commence New Clinical Trials
7/9/2018
LPLV marks the final steps toward completion of TLC599 trial for osteoarthritis (OA) pain Phase II topline results on-track for 2018 release Set to initiate enrollment of US Phase II pharmacokinetic (PK) trial for TLC599 Clearance received from the U.S. Food and Drug Administration (FDA) for the TLC590 and TLC178 Investigational New Drug (IND) applications, allowing Phase I/II trials to proceed in the...